The reserpine contribution to the development of psychiatry and its role in the neurobiological research;La contribución de la reserpina al desarrollo de la psiquiatría y su papel en la investigación neurobiológica

Revista de Psiquiatria de la Facultad de Medicina de Barcelona

Volumn 31, Issue 3, 2004, Pages 130-139

  Alamo, Cecilio ^a   Lopez Muñoz, Francisco ^a   Bhatara, Vinod S ^b   Cuenca, Eduardo ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Universidad de Dakota del Sur   (United States)

Author keywords

Antipsychotics; Depresion; Ethiological Hipothesis; Experimental Models; History of Medicine; Reserpine; Schizophrenia

Indexed keywords

3 O METHYLDOPAMINE; DOPAMINE; LEVODOPA; NEUROLEPTIC AGENT; NORADRENALIN; NORMETADRENALIN; RESERPINE;

ARTICLE; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; HISTORY OF MEDICINE; HUMAN; MONOAMINERGIC SYSTEM; PARKINSON DISEASE; PSYCHOPHARMACOLOGY; RAUWOLFIA; SCHIZOPHRENIA;

EID: 4544317152     PISSN: 02137429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Ayd FJ. Drug induced depression - fact or fallacy. NY State J Med 1958;58:354-6.
2. Battegay R. Forty-four years of psychiatry and psychopharmacology. En: The psychopharmacologists III (Healy D, interviewer). London: Arnold, 2000;371-94.
3. Bein HJ. Prejudices in pharmacology and pharmacotherapy: reserpine as a model for experimental research in depression. Pharmakopsychiat 1978;11:289-93.
4. Bein HJ. Biological research in the pharmaceutical industry with reserpine. En: Discoveries in Biological Psychiatry (Ayd FJ, Blackwell B, eds.). Baltimore: Ayd Medical Communications, 1984;142-54.
5. Berger PA. Medical treatment of mental illness. Science 1978;200:974-81.
6. Bertler A, Rosengren E. Occurrence and distribution of dopamine in brain and other tissues. Experientia 1959;15:10-1.
7. Bhatara VS, Sharma JN, Gupta S, Gupta YK. Rauwolfia serpentina: The first herbal antipsychotic. Am J Psychiat 1997;154:894.
8. Birkmayer W, Hornykiewicz O. Der L-3,4-Dioxyphenylalanin (DOPA)-Effek bei der Parkinson-Akinese. Wien Klin Wochenschr 1961;73:787-8.
9. Bourin M, Poncelet M, Chermat R, Simon P. The value of the reserpine test in psychopharmacology. Arzneim Forsch Drug Res 1983;33:1173-6.
10. th Annual Meeting of the American Psychiatric Association, 1959a;27abril-1mayo.
11. th Annual Meeting of the American Psychiatric Association, 1959b;27abril-1mayo.
12. Brill H, Patton RE. Clinical-statistical analysis of population changes in New York mental hospitals since introduction of psychotropic drugs. Am J Psychiatr 1962;119:1-20.
13. Brodie BB, Pletscher AP, Shore, PA. Evidence that serotonin has a role in brain function. Science 1955;122:968.
14. Brodie BB, Pletscher AP, Shore, PA. Possible role of serotonin in brain function and in reserpine action. J Pharmacol Exp Ther 1956;116:9.
15. Brodie BB, Olin JS, Kuntzman R, Shore PA. Possible interrelationship between release of brain norepinephrine and serotonin by reserpine. Science 1957;125:1293-4.
16. Cancro R. The introduction of neuroleptics: a psychiatric revolution. Psychiatr Serv 2000;51:333-5.
17. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959;11:490-3.
18. Carlsson A. Zur Frage der wirkungsweise einiger psychopharmaka. Psychiat Neurol 1960;140:220-2.
19. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatr 1978;135:164-73.
20. Carlsson A. A paradigm shift in brain research. Science 2001a;294:1021-4.
21. Carlsson A. A half-century of neurotransmitter research: impact on neurology and psychiatry (Nobel Lecture, 8 december 1999). Biosci Reports 2001b;21:691-710.
22. Carlsson A, Hillarp NA. Release of adrenaline from the adrenal medulla of rabbits produced by reserpine. Kungl Fysiogr Sällsk Lund Förhandl 1956;26:8.
23. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140-4.
24. Carlsson A, Lindqvist M, Magnusson T. 3,4-dihydroxy phenylalanine and 5-hydroxy tryptophan as reserpine antagonists. Nature 1957;180:1200.
25. Chessin M, Kramer ER, Scott CC. Modification of the pharmacology of reserpine and serotonin by iproniazid. J Pharmacol Exp Ther 1957;119:453-460.
26. Colodrón A. Psiquiatría Biológica: Historia y método. En: Fundamentos biológicos en psiquiatría (Cervilla JA, García-Ribera C, eds.). Barcelona: Masson S.A., 1999; 3-9.
27. Costa E, Garrattini S, Valzelli L. Interactions between reserpine, chlorpromazine and imipramine. Experientia 1960;15:461-3.
28. Cuenca E, Costa E, Kintzman R, Brodie BB. The methyl ether of methyl reserpate; a prototype of reversible short-acting tranquilizing agents. Med Exp 1961;5:20-4.
29. Curzon G. How reserpine and chlopromazine act: the impact of key discoveries on the history of psychopharmacology. Trends Pharmacol Sci 1990;11:61-3.
30. Davis JM, Cole JO. Fármacos antipsicóticos. En: Tratado de Psiquiatría (Freedman AM, Kaplan HI, Sadock BJ, eds.). Barcelona: Editorial Salvat, 1982.
31. Degkwitz R, Frowein R, Kulenkampff C, Mohs U. Über die Wirkungen des L-DOPA beim Menschen und deren Beeinflussung durch Reserpin, Chlorpromazin, Iproniazid uns Vitamin B6. Klin Wochenschr 1960; 38:120-3.
32. Delay J, Deniker P. Caractéristiques psycho-physiologiques des médicaments neuroléptiques. En: Psychotropic drugs (Delay J, Deniker P, eds.). Elsevier, Amsterdam, 1957;485-501.
33. Delay J, Deniker P, Harl JM, Grasset A. Traitements des états confussionels par le chlorte de deméthylaminopropyl-N-chloro- phénothiazine (4560 RP). Ann Méd Psychol 1952;110:398-403.
34. Delay J, Deniker P, Tardieu Y, Lempérière T. Premiers essais en thérapeutique psychiatrique de la réserpine, alcaloïde nouveau de Rauwolfia serpentins. CR 52° Congrés des Médecins Aliénistes et Neurologistes de Langue Francaise, Liège, 20 Julio, 1954;836-41
35. Duval AM, Goldman D. The new drugs (chlorpromazine and reserpine): administrative aspects. Ment Hosp 1956;7:30-4.
36. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytiramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 1960;38:1236-9.
37. Geller JL. The last half-century of psychiatric services as reflected in Psychiatric Services. Psychiatr Sev 2000;51:41-67.
38. Ginestet D. Les neuroleptiques. Développement et situation actuelle. L'Encephale 1991;XVII:149-52.
39. Healy D, Savage M. Reserpine exhumed. Br J Psychiatry 1998;172:376-8.
40. Hollinger M. Effect of reserpine, alpha-methyl-p-tyrosine, p-chlorophenylalanine and pargyline on levorphanol-induced running activity in mice. Arch Int Pharmacodyn Ther 1969;179:419-24.
41. Holzbauer M, Vogt M. Depression by reserpine of the noradrenergic concentration in the hypothalamus of the cat. J Neurochem 1956;1:8-11.
42. Kline NS. Use of Rauwolfia serpentina benth in neuropsychiatric conditions. Ann NY Acad Sci 1954;59:107-32.
43. Lehmann HE. A clinical psychopharmacologist remember and takes stock. En: Psychopharmacology: impact on clinical psychiatry (Morgan DW, ed.). Ishiyaku EuroAmerica, Inc. Publishers, St. Louis, 1985;259-66.
44. López-Muñoz F, Alamo C, Cuenca E. La "Década de Oro" de la Psicofarmacología (1950-1960): Trascendencia histórica de la introducción clínica de los psicofármacos clásicos, Psiquiatria.COM (electronic journal), Sep, 4 (3), URL: http://www.psiquiatria.com/psiquiatria/revista/47/1800/? ++interactive, 2000.
45. López-Muñoz F, Alamo C, Cuenca E. Aportación de la clorpromazina al desarrollo de la psiquiatría. Arch Psiquiatr 2003;66:15-34.
46. Mayer-Gross W. A survey of the pharmacological possibilities in psychiatry. L'Encephale 1956;N° Spécial:7-12.
47. Metzger RR, Brown JM, Sandoval V, Rau KS, Elwan MA, Miller GW, Hanson GR, Fleckenstein AE. Inhibitory effect of reserpine on dopamine transporter function. Eur J Pharmacol 2002;456:39-43.
48. Pletscher A. On the eve of the neurotransmitter era in biological psychiatry. En: The rise of psychopharmacology and the story of CINP (Ban TA, Healy D, Shorter E, eds.). Animula Publishing House, Budapest, 1998;110-5.
49. Pöldinger W. Compendio de psicofarmacologia. Basel: Hoffmann-La Roche and CIE, 1972;27.
50. Rance AM, Jurquet A, Roger J. Remarques sur la thérapeutique des affections psychiatriques par la chlorpromazine et la réserpine. L'Encephale 1956; Numéro Spécial:177-87.
51. Sarwer-Forner GJ, Ogle W. Psychosis and enhanced anxiety produced by reserpine and chlorpromazine. Can Med Assoc J 1955;74:526-32.
52. Slater IH, Rathbun RC, Kattau R. Role of 5-hydroxytryptaminergic and adrenergic mechanism in antagonism of reserpine-induced hypothermia in mice. J Pharm Pharmacol 1979;31:108-10.
53. Snyder SH. The dopamine hypothesis of schizophrenia: focus on dopamine receptor. Am J Psychiatr 1976;133:197-202.
54. Tedeschi DH, Fowler PJ, Fujita T, Miller RB. Mechanisms underlying reserpine-induced ptosis and blepharospasm: evidence that reserpine decreases central sympathetic outflow in rats. Life Sci 1967;6:515-23.
55. Valdecasas FG, Cuenca E, Morales M. Acción de la reserpina sobre la presión arterial en gatos espinales tratados con inhibidores de la aminoxidasa. Granada: Libro de Actas de la V Reunion Nacional de la Sociedad Espanola de Ciencias Fisiológicas, 1958;305-9.
56. Valdecasas FG, Salvá JA, Cuenca E. Acción periférica y central de la reserpina. Madrid: Libro de Actas de la V Reunión Nacional de la Sociedad Española de Ciencias Fisiológicas, 1959;333-4.
57. Valdecasas FG, Cuenca E, Rodriguez L. Fenómeno reserpínico en el conducto deferente de la rata. Pamplona: Libro de Actas de la IX Reunión Nacional de la Sociedad Española de Ciencias Fisiológicas, 1965;177-9.
58. Van Rossum J. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Therap 1966;160:492-4.
59. Xiao Q, Pawlyk A, Tejani-Butt SM. Reserpine modulates serotonin transporter mRNA level in the rat brain. Life Sci. 1999;64:63-8.